Arena's (ARNA) Heart Failure Candidate Gets Fast Track Status
Posted on Friday January 17, 2020
The FDA grants fast track status to Arena's (ARNA) early-stage candidate, APD418, for the treatment of decompensated heart failure.
FDA Grants Fast Track Designation to Arena Pharmaceuticals' APD418 for Development in Decompensated Heart Failure Patients
Posted on Thursday January 16, 2020
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for APD418, a β3-adrenergic receptor (AdrR) antagonist and cardiac myotrope, in development for the treatment of decompensated heart failure (DHF).
Arena Pharmaceuticals Appoints Joan Schmidt as Executive Vice President, General Counsel and Secretary
Posted on Monday January 13, 2020
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the appointment of Joan Schmidt as Executive Vice President, General Counsel and Secretary. Ms. Schmidt will join Arena formally in March 2020 and report to Amit D. Munshi, Arena's President and Chief Executive Officer.
2019 Review: Top Hedge Fund Stocks vs. Arena Pharmaceuticals, Inc. (ARNA)
Posted on Wednesday January 08, 2020
It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren't usually symmetrically distributed and index […]
